The short version
- Why people research itMitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
- What the evidence isThe human record is Soviet and post-Soviet clinical work — real patients and real endpoints, published in Russian and rarely replicated to Western standards.
- What to watchBlood in urine while using Vesilut.
How Vesilut works
Khavinson urinary-bladder bioregulator — proposed to support bladder cell function and urogenital aging.
Correcting this site's own catalog line first. The record here has said that nothing distinguishes Vesilut from Chitomur.
What the preparation is. A urinary-bladder peptide complex: extracted tissue, size-fractionated, standardized by total peptide content. No sequence, therefore no formula, no exact mass, no isoelectric point, no charge to compute.
- Injectable
On the goal map: Liver, kidney, gut & lung (Organ-specific bioregulation)
Research on Vesilut5 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Human clinical evidence
The human record is Soviet and post-Soviet clinical work — real patients and real endpoints, published in Russian and rarely replicated to Western standards.
Correlative data
The other urinary-tract bioregulator, overlapping heavily with Chitomur in positioning. The two are indistinguishable in composition, because neither vendor publishes one — but they are no longer indistinguishable in evidence: Chitomur has a randomized blind human study indexed under its trade name and this one has none. Worth knowing before buying both.
How the mechanism reads
A urinary bladder peptide preparation proposed to support bladder cell function in urogenital ageing.
MechanisticTwo things at once: the mechanism is a real, testable hypothesis with published cell-level work behind it, and essentially all of that work is one group's, unreplicated at scale.
MechanisticSame placebo-sensitivity caveat as Chitomur: the endpoint is symptomatic and self-reported, which is the condition under which uncontrolled evidence is least reliable.
Mechanistic
Sources
- Gomberg VG, Ryzhak AP, Lyutov RV. Correction of age related bladder function decrease with peptide geroprotector in women. Advances in Gerontology 2013;26(2):309–314 · PMID 28976156
- Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. International Journal of Molecular Sciences 2022;23(14):7733 · PMID 35887081
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules 2021;26(22):7053 · PMID 34834147
- Alsulaimani RA, Quinn TJ (independent — not the Khavinson group). The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis. Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
- Kolchina N, Khavinson V, Linkova N, Yakimov A, Baitin D, Afanasyeva A, Petukhov M. Systematic search for structural motifs of peptide binding to double-stranded DNA. Nucleic Acids Research 2019;47(20):10553–10563 · PMID 31598715
- Werle M, Bernkop-Schnurch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 2006 · PMID 16622600
- Drucker DJ. Advances in oral peptide therapeutics. Nature Reviews Drug Discovery 2020 · PMID 31848464
Vesilut safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Blood in the urine that has not been explained: bladder cancer must be excluded first.
- An active urinary infection.
- Pregnancy or breastfeeding: no data for this bladder peptide.
- Under 18: urinary-tract peptide signaling in growing tissue is untested.
What’s expected
- Probably no effect you can feel; the claim is support of bladder cell function.
- Mild soreness at the application spot.
- Any urinary comfort gain would be gradual.
Watch for
- Blood in urine while using Vesilut.
- Burning urination with fever.
- Being unable to empty the bladder.
- Flank pain while using Vesilut.
Labs that tell you it’s working
- Urinalysis, Routine
- Comprehensive Metabolic Panel (CMP)
- Cystatin C with eGFR
- hs-CRP (C-Reactive Protein, High Sensitivity)
Vesilut is a Khavinson urinary-bladder peptide with limited studies; urine and kidney labs are the first-line checks.
Bloodwork to runHow you would know it is working: 8 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
Vesilut FAQ4 common questions
- Is Vesilut approved for human use?
- No. Vesilut is a research compound.
- What is Vesilut researched for?
- Mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
- Which labs show whether it's doing anything?
- Urinalysis, Routine; Comprehensive Metabolic Panel; Cystatin C with eGFR; hs-CRP: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Vesilut: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



